Neil Stahl, EVP Research and Development at REGENERON PHARMACEUTICALS, INC. (REGN), sold 10,694 shares at $1086.15 ($10.6M) on 2024-08-08, disclosed to the SEC on 2024-08-12.
Scheduled sale ($10.6M) by EVP Research and Development under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1081.83 | 100 | $108K | 1.0% |
| 2 | $1082.69 | 200 | $217K | 2.0% |
| 3 | $1083.76 | 1,006 | $1.1M | 10.3% |
| 4 | $1083.76 | 1,006 | $1.1M | 10.3% |
| 5 | $1084.61 | 1,883 | $2.0M | 19.2% |
| 6 | $1084.61 | 1,883 |
| $2.0M |
| 19.2% |
| 7 | $1085.01 | 1,708 | $1.9M | 17.4% |
| 8 | $1085.01 | 1,708 | $1.9M | 17.4% |
| 9 | $1086.15 | 300 | $326K | 3.1% |
| 10 | $0.00 | 900 | $0 | 0.0% |
| Total | $993.28 avg | 10,694 | $10.6M | 100% |
| Filing → |
| REGN | SELL | 2022-08-08 | $28.4M | — | Filing → |
| REGN | SELL | 2021-05-18 | $18.2M | — | Filing → |
| REGN | SELL | 2020-05-11 | $5.9M | — | Filing → |